STOCKS TELEGRAPH

Tag: NURO Stock Price

  • Elevating Shareholder Value: NeuroMetrix (NURO) Unveiled Forward-Thinking Measures

    Elevating Shareholder Value: NeuroMetrix (NURO) Unveiled Forward-Thinking Measures

    NeuroMetrix, Inc. (NASDAQ: NURO) is experiencing a significant surge in its stock value during the current  trading session, marking a notable 17.13% increase, with shares trading at $4.25 as of the last check. This uptick in NURO stock price closely followed the revelation by the company of steps taken to enhance shareholder value.

    NeuroMetrix (NURO) unveiled measures to bolster shareholder value today, spurred by insights and counsel from one of its prominent stakeholders, Ephraim Fields of Echo Lake Capital. The NeuroMetrix Board ratified the selection of Joshua S. Horowitz as a fresh independent director for a one-year term.

    Mr. Horowitz brings to the table a wealth of experience as a seasoned investor spanning over 22 years, notably serving as a portfolio manager at Palm Management (US) LLC since January 2012. Additionally, he assumed the role of Director at Barnwell, Inc. in February 2023 and was appointed chairman of the Board of Directors at BK Technologies in December 2023.

    His extensive investment acumen and boardroom proficiency, especially within the realm of micro and small cap enterprises, render him particularly apt to guide NeuroMetrix through its ongoing strategic assessment. In parallel, NeuroMetrix has opted to discontinue its at-the-market (ATM) equity arrangement previously established with Ladenburg Thalmann & Co., Inc. on October 22, 2021.

    Highlighting recent developments, NeuroMetrix underscored a substantial study corroborating the efficacy of DPNCheck in conjunction with standard EKG or as a standalone tool for accurate detection of diabetic peripheral neuropathy (DPN). Hayashi and collaborators scrutinized 167 patients afflicted with Type 1 or Type 2 diabetes, employing a gold standard nerve conduction study as the reference for DPN diagnosis.

    By leveraging DPNCheck measurements, patient age, and the coefficient of variation of R-R intervals (CVR-R)—a metric assessing autonomic function standardly generated by EKG machines—the authors derived a predictive algorithm. The amalgamation of DPNCheck with CVR-R exhibited robust diagnostic efficacy, as evidenced by an area under the receiver operating curve (AUC) of 0.88.

    Similarly robust performance was observed when DPNCheck was employed in isolation. The authors concluded that integrating DPNCheck with electrocardiography simplifies the diagnosis of DPN, rendering it widespread, reproducible, and dependable.

  • How Has The NeuroMetrix (NURO) Stock Appreciated In After Hour Trades?

    How Has The NeuroMetrix (NURO) Stock Appreciated In After Hour Trades?

    In after-market trading hours on Tuesday, NeuroMetrix Inc. (NURO) advanced 7.06% to $3.64. During the last trading session, NeuroMetrix stock gained 0.29% to close at $3.40. A range of $3.355 to $3.75 was the price range of the NURO stock. NURO stock surged on the news that its device would be utilized in a clinical trial.

    What kind of technology did NURO have?

    NeuroMetrix is a global medical device company that focuses on non-invasive medical device development and global commercialization for the diagnosis and treatment of diseases of the nervous system.

    Three NURO products are commercially available.

    • DPNCheck is a device that detects peripheral neuropathies at the point of care.
    • Developed for in-office evaluation of focal neuropathies, ADVANCE is a diagnostic device which provides automated nerve conduction studies.
    • Quell is an over-the-counter wearable neuro stimulating device indicated for symptomatic relief of chronic lower extremity pain.

    Yesterday, NeuroMetrix announced it would employ Quell technology in a randomized, double-blinded study.

    • Transcutaneous electrical nerve stimulation (TENS) has been tested in order to determine whether it is a feasible, effective, and acceptable way to relieve pain in patients with NMOSD.
    • Michael Levy is the principal investigator at Massachusetts General Hospital’s NMO Clinic and Research Laboratory.
    • A total of 46 NMOSD patients will be enrolled in the current trial.
    • Four weeks will be devoted to the active and sham Quell trials.
    • Subjects will then be subject to a 4-week active treatment phase under open label.
    • Based on the 11-point numerical pain scale, the baseline to 4-week pain intensity change is the primary outcome measure.

    Is the Quell going to be used for anything?

    The results of this rigorous randomized controlled trial will contribute to a growing body of evidence demonstrating the benefits of NURO’s Quell technology in chronic pain conditions with neuropathic pain components. NeuroMetrix (NURO)’s device may be able to help patients with neuropathic pain, which has significant unmet clinical needs.